https://www.selleckchem.com/products/repsox.html
To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). This phase III, randomised, double-blind, placebo-controlled study enrolled patients aged ≥18 years diagnosed with active AS, meeting the modified New York criteria, with centrally read radiographs, and an inadequate response or intolerance to ≥2 non-steroidal anti-inflammatory drugs. Patients were randomised 11 to receive tofacitinib 5 mg two times per day or placebo for 16 weeks. After week 16, all patients received open-label tofaci
Like
Comment
Share
